Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.095 USD | -5.02% | -4.72% | -19.20% |
05/06 | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
04/06 | FDA panel to review psychedelic drug MDMA for first time | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.20% | 51Cr | |
+57.67% | 5.93TCr | |
+43.17% | 4.02TCr | |
-5.04% | 3.99TCr | |
-5.56% | 2.86TCr | |
+14.98% | 2.73TCr | |
-21.05% | 1.92TCr | |
+32.97% | 1.26TCr | |
+2.68% | 1.25TCr | |
+25.83% | 1.23TCr |
- Stock Market
- Equities
- CMPS Stock
- News COMPASS Pathways plc
- COMPASS Pathways : Gets US Patent for Depressive Disorder Treatment